Navigation Links
BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing'

ARLINGTON, Va., March 3 /PRNewswire-USNewswire/ -- BNA Books, a division of specialized news and information publisher BNA, announces the publication of the 2009 Cumulative Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing. The main volume and supplement are published by BNA Books with the American Bar Association (ABA) Health Law Section.


Pharmaceutical Law: Regulation of Research, Development, and Marketing is the only resource that provides expert commentary and authoritative insights into a comprehensive range of pharmaceutical law issues. No other single volume discusses these complex issues in the detail required for transactional health care attorneys to adequately advise their clients on the opportunities—and the liabilities—in this industry. This treatise:

  • Addresses the considerable fraud and abuse risks unique to this submarket of the health                care industry
  • Covers off-label marketing—selling a drug for a purpose other than its intended use
  • Explains and discusses the other hot risks areas—including the potential for antitrust, securities law, and other compliance violations
  • Discusses the securities law reporting obligations of drug companies for material events (such as the rejection of approval of NDAs), and how to protect clinical research subjects

The 2009 Cumulative Supplement is updated with new topics, including:

  • Kennedy-Enzi, the Enhancing Drug Safety and Innovation Act of 2006
  • The Food and Drug Administration Amendments Act of 2007
  • The FDA and preemption in the context of labeling and drug safety
  • FDA authority to regulate tobacco products
  • Changes to DTC marketing made by the Food and Drug Administration Amendments Act of 2007
  • The Health Information Technology for Economic and Clinical Health (HITECH) Act
  • HIPAA enforcement
  • Lanham Act violations
  • Class actions

This treatise also offers authoritative explanations of the complex inter-relationships between the pharmaceutical industry, health care delivery system, insurers, and regulators.

Michael E. Clark is the author of the treatise and its supplement. Mr. Clark is a member in Hamel Bowers & Clark LLP. He has a distinguished background in government and private litigation, having served as Chief of the Criminal Division of the U.S. Attorney's Office for the Southern District of Texas from 1993−1997.

BNA is a leading private publisher of news and information products for professionals in law and business. In addition to Pharmaceutical Law: Regulation of Research, Development, and Marketing with 2009 Cumulative Supplement, BNA's Book Division publishes Pharmaceutical Patent Law; Health Care Fraud and Abuse; Prosecuting and Defending Health Care Fraud; Managed Care Litigation; E-Health Business and Transactional Law; and other titles in legal specialties. For a free BNA Books catalog, call 1-800-960-1220 or send an e-mail request to The BNA Books website, including an online catalog, can be found at

The 2009 Cumulative Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing may be purchased alone (344 pp. Softcover/Order#1823-PRY9/$220.00 plus tax, shipping, and handling), or with the main volume (899 pp. Hardcover/Order #9823-PRY9/$385.00 plus tax, shipping, and handling) from BNA Books, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1-800-960-1220. Fax orders: 1-732-346-1624. A 10% discount is available on print copies of books when ordering from the website at Please note that discounts cannot be combined.


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/25/2015)... total global healthcare industry is expected to grow at a ... has the highest projected growth at 12.7%, and ... ), is second with growth projected at 11.5%. ... In 2013-2014, total government funded healthcare was nearly 68%. Federal ... in 2013-2014. In real terms, out of pocket expenditure increased ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology:
(Date:11/25/2015)... OK (PRWEB) , ... November 25, 2015 , ... On ... International training center for the Narconon network, announced the release of a new cutting ... 1966 the Narconon organization has been working with drug- and alcohol-addicted individuals with the ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... 25, 2015 , ... “While riding the bus, I saw a passenger in ... there had to be a convenient and comfortable way to protect them from bad ... individuals to safely travel during cold or inclement weather. In doing so, it ensures ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
Breaking Medicine News(10 mins):